Therapy News and Research

RSS

Glutaminase inhibitor: New potential target for brain tumors

Scientists at Johns Hopkins have identified a compound that could be used to starve cancers of their sugar-based building blocks. The compound, called a glutaminase inhibitor, has been tested on laboratory cultured, sugar-hungry brain cancer cells and, the scientists say, may have the potential to be used for many types of primary brain tumors.

19 Nov 2010

AVEO announces results from tivozanib Phase 1b clinical trial for advanced gastrointestinal cancers

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced results from a Phase 1b clinical trial evaluating the company's lead product candidate, tivozanib, a highly potent and selective inhibitor of VEGF receptors 1, 2, and 3, in combination with FOLFOX6, a standard chemotherapy regimen, in patients with advanced gastrointestinal (GI) cancers.

19 Nov 2010

COG to conduct Phase I REOLYSIN trial in pediatric patients with solid tumors

Oncolytics Biotech Inc. announced today that the Children's Oncology Group (COG) intends to conduct a Phase I trial of REOLYSIN in combination with cyclophosphamide in pediatric patients with relapsed or refractory solid tumors.

19 Nov 2010

OXiGENE updates data on FALCON trial for non-small cell lung cancer

OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that it presented updated safety and clinical activity data from the FALCON trial, a randomized, controlled Phase 2 study of ZYBRESTAT(TM) (CA4P) in patients with non-small cell lung cancer (NSCLC).

19 Nov 2010

Advanced Life Sciences submits application to FDA for ALS-886 to treat ARDS

Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced that the Company has applied to the U.S. Food and Drug Administration for orphan drug designation for ALS-886, a novel therapy to reduce and prevent tissue damage, for the treatment of Acute Respiratory Distress Syndrome (ARDS).

19 Nov 2010

YM BioSciences expands CYT387 Phase I/II clinical trial for myelofibrosis in five sites

YM BioSciences Inc., today reported that the Phase I/II clinical trial for its orally available JAK1/JAK2 inhibitor, CYT387, in patients with myelofibrosis has been expanded to five sites. Of the additional sites, the Stanford Cancer Center (Stanford, California) under Principal Investigator Jason Gotlib, MD has already commenced enrolling patients.

19 Nov 2010

Aastrom announces interim analysis of Phase 2b RESTORE-CLI clinical trial for treatment failure

Aastrom Biosciences, Inc., a leading developer of expanded autologous cellular therapies for the treatment of severe cardiovascular diseases, today announced that an interim analysis of all 86 patients enrolled in the company's Phase 2b RESTORE-CLI clinical trial shows that the study achieved both its primary safety endpoint and primary efficacy endpoint of time to first occurrence of treatment failure.

19 Nov 2010

Spectrum to present four key belinostat data for solid cancers at ASH annual meeting

Spectrum Pharmaceuticals, Inc., a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, today announced four key belinostat data presentations at the 52nd Annual Meeting of the American Society of Hematology (ASH), being held at the Orange County Convention Center in Orlando, Florida, December 4-7, 2010.

19 Nov 2010

Cerulean presents data on CRLX101, CRLX288 study for cancer at EORTC-NCI-AACR Symposium

Cerulean Pharma Inc., a leader in designing and developing nanopharmaceuticals, today announced that the Company's senior executives presented at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, ongoing in Berlin, Germany.

19 Nov 2010

FDA approves new drug application for NEXTERONE Premixed Injection

Prism Pharmaceuticals, Inc. announced today that the U.S. Food & Drug Administration has approved the supplemental new drug application for NEXTERONE (amiodarone HCl) Premixed Injection, the first and only premixed intravenous (IV) bag formulation of the antiarrhythmic agent amiodarone IV.

19 Nov 2010

Clinical data of CU-201, CUDC-101 presented at EORTC-NCI-AACR Symposium

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced the presentation of data in two poster presentations at the 22nd EORTC-NCI-AACR Symposium on "Molecular Targets and Cancer Therapeutics," held in Berlin, Germany, November 16-19.

19 Nov 2010

Scientific breakthrough for high blood pressure

Melbourne researchers have successfully used a new machine that reduces increased blood pressure with the help of radio waves. High blood pressure plagues nearly one fourth to a third of the Australian population and can lead to heart disease, stroke and kidney failure. Almost half of sufferers do not even show any significant improvement by using the drugs available in the market for high blood pressure.

18 Nov 2010

Multiple epidemiological parameters drive increase in drug-treatment opportunities for pancreatic cancer: Decision Resources

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds significant trends in multiple epidemiological parameters to be driving the increase in drug-treatment opportunities for pancreatic cancer over the period 2009 to 2024, including population aging, increasing risk of recurrence following resection and modest improvements in survival.

18 Nov 2010

NAVISTAR THERMOCOOL Catheter improves quality of life in patients with atrial fibrillation

According to data appearing today in Circulation Cardiovascular Quality and Outcomes, patients with a common heart rhythm disorder, called atrial fibrillation, who were treated with catheter ablation using the NAVISTAR THERMOCOOL Catheter, reported markedly fewer symptoms and substantially improved quality of life than patients treated with antiarrhythmia drugs at one year.

18 Nov 2010

Circassia announces positive result from phase II T-cell vaccine study for house dust mite allergy

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced successful clinical results from a phase II study of its T-cell vaccine targeting house dust mite allergy.

18 Nov 2010

Study finds sfrp2 protein may play a role in accelerating heart muscle repair

Heart tissue and stem cells spring into action to begin repairing muscle damaged in a heart attack, and researchers at Duke University School of Medicine found that a protein naturally produced in the body may potentially play a role in accelerating heart muscle repair.

18 Nov 2010

The Court upheld valid claims of two KCI patents

Kinetic Concepts, Inc. today announced that the Court of Appeal of England and Wales has upheld the validity of important claims of two KCI patents relating to negative pressure wound therapy. The Court also found that NPWT products marketed by Smith & Nephew plc infringe one of the patents.

18 Nov 2010

Multidisciplinary clinic approach can improve survival in patients with aggressive prostate cancer

A research team from the National Cancer Institute (NCI) designated Kimmel Cancer Center (KCC) at Jefferson has concluded for the first time that a multidisciplinary clinic approach to aggressive prostate cancer can improve survival in patients. The results from the 15-year study of the multidisciplinary clinic can be found in the November issue of Journal of Oncology Practice.

18 Nov 2010

MEDRAD to offer RSNA attendees hands-on demonstration on P3T PA software

MEDRAD will offer RSNA attendees hands-on demonstrations of personalized-protocol software that individualizes CT Pulmonary Angiography (CTPA) contrast dosing, and has proven to increase the percentage of diagnostic-quality studies to rule out Pulmonary Embolism (PE) when compared to the institution's standard protocol potentially obviating the need to rescan the patient.

18 Nov 2010

Health Net partners with DoD for Major Depression Disease Management Program

Health Net Federal Services, LLC, part of the Government Contracts segment of Health Net, Inc. (NYSE:HNT), today announced its Major Depression Disease Management Program established in partnership with the Department of Defense (DoD) for TRICARE beneficiaries, ages 18-64. TRICARE is the DoD's health care plan for active duty and retired service members and their families.

18 Nov 2010

Therapy News and Research

Glutaminase inhibitor: New potential target for brain tumors

AVEO announces results from tivozanib Phase 1b clinical trial for advanced gastrointestinal cancers

COG to conduct Phase I REOLYSIN trial in pediatric patients with solid tumors

OXiGENE updates data on FALCON trial for non-small cell lung cancer

Advanced Life Sciences submits application to FDA for ALS-886 to treat ARDS

YM BioSciences expands CYT387 Phase I/II clinical trial for myelofibrosis in five sites

Aastrom announces interim analysis of Phase 2b RESTORE-CLI clinical trial for treatment failure

Spectrum to present four key belinostat data for solid cancers at ASH annual meeting

Cerulean presents data on CRLX101, CRLX288 study for cancer at EORTC-NCI-AACR Symposium

FDA approves new drug application for NEXTERONE Premixed Injection

Clinical data of CU-201, CUDC-101 presented at EORTC-NCI-AACR Symposium

Scientific breakthrough for high blood pressure

Multiple epidemiological parameters drive increase in drug-treatment opportunities for pancreatic cancer: Decision Resources

NAVISTAR THERMOCOOL Catheter improves quality of life in patients with atrial fibrillation

Circassia announces positive result from phase II T-cell vaccine study for house dust mite allergy

Study finds sfrp2 protein may play a role in accelerating heart muscle repair

The Court upheld valid claims of two KCI patents

Multidisciplinary clinic approach can improve survival in patients with aggressive prostate cancer

MEDRAD to offer RSNA attendees hands-on demonstration on P3T PA software

Health Net partners with DoD for Major Depression Disease Management Program

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News